Search clinical trials for: E7389

Total 71 results

Eisai Inc.

Completed

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

France, Germany, Belgium, Denmark, Poland
Eisai Co., Ltd.

Completed

Phase I Clinical Study of E7389

Cancer

Japan
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Eisai Inc.

Completed

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eisai Co., Ltd.

Active, not recruiting

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Solid Tumor

Japan
Eisai Inc.

Completed

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands
Eisai Inc.

Completed

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Cancer

United States, Austria, India
National Cancer Institute (NCI)

Completed

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
Eisai Inc.

Completed

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer

Netherlands
Eisai Inc.

Completed

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Non-Small-Cell Lung Carcinoma

United States
Eisai Inc.

Completed

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Breast Cancer

United States
Eisai Inc.

Completed

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Prostate Cancer

United States
Dana-Farber Cancer Institute

Completed

Eribulin in HER2 Negative Metastatic BrCa

Breast Cancer

United States
Eisai Inc.
Eisai Limited

Completed

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Breast Cancer

United States, Canada
Eisai Co., Ltd.

Completed

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Breast Cancer

Japan
Eisai Inc.

Completed

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Breast Neoplasms

United States
Eisai Inc.

Completed

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

Cancer

United States
Eisai Inc.

Completed

Study of E7389 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Limited

Completed

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Breast Cancer

United States
Eisai Limited

Suspended

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

Healthy Volunteers

United Kingdom
Eisai Inc.

Completed

A Food-Effect Study of E7386 in Healthy Participants

Food Effect in Healthy Participants

United States
Eisai Inc.

Recruiting

Study of E7386 in Participants With Selected Advanced Neoplasms

Advanced Neoplasms

United States, United Kingdom
University of Southern California
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Recurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical Cancer

United States
Eisai Inc.
Eisai Limited

Completed

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Russian Federation, Italy, Belgium, Canada, South Africa, France, United States, Switzerland, Argentina, Australia, Austria, Brazil, Croatia, Czechia, Hungary, Poland, Spain
University of Washington
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

Recurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer

United States
Eisai Co., Ltd.

Completed

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (HAL03T)

Sarcoma, Soft Tissue

Japan
Hope Rugo, MD
Susan G. Komen Breast Cancer Foundation; Plexxikon

Completed

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Eisai Korea Inc.

Completed

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Locally Advanced or Metastatic Breast Cancer

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI); Eisai Inc.

Completed

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Primary Brain Tumor | Metastatic Malignant Neoplasm in the Adult Brain

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

Canada
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Eisai Co., Ltd.

Active, not recruiting

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Colorectal Neoplasms | Gastrointestinal Tumors | Solid Neoplasms

Japan
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)

Breast Neoplasm

United States
University Hospital Muenster
Basilea Pharmaceutica International Ltd

Terminated

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus (AliCLE)

Lupus Erythematosus, Cutaneous

Germany
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eisai Inc.

Completed

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Breast Cancer | Estrogen Receptor Positive Tumor

United States
Eisai Co., Ltd.
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Solid Neoplasms

Japan
Medicines for Malaria Venture
Mahidol University

Completed

Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection

Malaria, Falciparum | Malaria, Vivax
Eisai Co., Ltd.

Completed

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Breast Cancer | Breast Tumors | Triple Negative Breast Cancer | Cancer of Breast | HER2-Negative Breast Cancer

China
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Ovarian Cancer | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation
Northwestern University
Eisai Inc.

Unknown

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Baghdad

Unknown

Effect of Topical Melatonin Application on Dental Implant Osseointegration and Marginal Bone Level

Alveolar Bone Loss

Iraq
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma

United States, Canada

3

Subscribe